KR20250130696A - 신규한 인터루킨-15 (ｉｌ-15) 융합 단백질 및 이의 용도 - Google Patents
신규한 인터루킨-15 (ｉｌ-15) 융합 단백질 및 이의 용도Info
- Publication number
- KR20250130696A KR20250130696A KR1020257027222A KR20257027222A KR20250130696A KR 20250130696 A KR20250130696 A KR 20250130696A KR 1020257027222 A KR1020257027222 A KR 1020257027222A KR 20257027222 A KR20257027222 A KR 20257027222A KR 20250130696 A KR20250130696 A KR 20250130696A
- Authority
- KR
- South Korea
- Prior art keywords
- domain
- ser
- val
- fusion protein
- leu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862689051P | 2018-06-22 | 2018-06-22 | |
| US62/689,051 | 2018-06-22 | ||
| KR1020217002145A KR102848197B1 (ko) | 2018-06-22 | 2019-06-20 | 신규한 인터루킨-15 (ｉｌ-15) 융합 단백질 및 이의 용도 |
| PCT/US2019/038210 WO2019246379A1 (en) | 2018-06-22 | 2019-06-20 | Novel interleukin-15 (1l-15) fusion proteins and uses thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217002145A Division KR102848197B1 (ko) | 2018-06-22 | 2019-06-20 | 신규한 인터루킨-15 (ｉｌ-15) 융합 단백질 및 이의 용도 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20250130696A true KR20250130696A (ko) | 2025-09-02 |
Family
ID=68984274
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020257027222A Pending KR20250130696A (ko) | 2018-06-22 | 2019-06-20 | 신규한 인터루킨-15 (ｉｌ-15) 융합 단백질 및 이의 용도 |
| KR1020217002145A Active KR102848197B1 (ko) | 2018-06-22 | 2019-06-20 | 신규한 인터루킨-15 (ｉｌ-15) 융합 단백질 및 이의 용도 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217002145A Active KR102848197B1 (ko) | 2018-06-22 | 2019-06-20 | 신규한 인터루킨-15 (ｉｌ-15) 융합 단백질 및 이의 용도 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12319722B2 (https=) |
| EP (1) | EP3810171B1 (https=) |
| JP (2) | JP7440102B2 (https=) |
| KR (2) | KR20250130696A (https=) |
| CN (2) | CN112584851B (https=) |
| AU (2) | AU2019288471B2 (https=) |
| CA (1) | CA3102821A1 (https=) |
| WO (1) | WO2019246379A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU24546B1 (es) * | 2016-12-30 | 2021-09-07 | Ct Ingenieria Genetica Biotecnologia | Composición vacunal que comprende un mutante de la interleucina-15 humana |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| CN109705211B (zh) | 2017-10-26 | 2020-08-18 | 苏州复融生物技术有限公司 | 一种IgG1 Fc单体及其应用 |
| US20220002370A1 (en) | 2018-09-27 | 2022-01-06 | Xilio Development, Inc. | Masked cytokine polypeptides |
| JP7807076B2 (ja) * | 2019-12-13 | 2026-01-27 | キュージーン インコーポレイテッド | 新規インターロイキン－１５（ｉｌ－１５）融合タンパク質およびその使用 |
| TW202214290A (zh) * | 2020-04-22 | 2022-04-16 | 瑞士商諾華公司 | 異源二聚體人介白素－１５（ｈｅｔｉｌ－１５）之藥物組成物及藥物產品 |
| KR102863510B1 (ko) * | 2020-08-03 | 2025-09-23 | 난트셀, 인크. | Il-15 초작용제에 대한 약물-특이적 약동학 검정 (drug-specific pharmacokinetic assay for il-15 superagonist cross-reference to related applications) |
| WO2022045849A1 (ko) * | 2020-08-31 | 2022-03-03 | 주식회사 지아이셀 | Il15 단백질, il15 수용체 알파 단백질, fc 도메인 및 il2 단백질을 포함하는 융합단백질 및 이의 용도 |
| JP2023540629A (ja) * | 2020-09-16 | 2023-09-25 | ベイジーン リミテッド | インターロイキン１５構築物及び使用方法 |
| WO2022115865A2 (en) | 2020-11-25 | 2022-06-02 | Xilio Development, Inc. | Tumor-specific cleavable linkers |
| CN113321736B (zh) * | 2020-12-30 | 2024-01-09 | 苏州复融生物技术有限公司 | 一种长效化白介素15融合蛋白及其制备方法和应用 |
| US20250197525A1 (en) * | 2021-04-28 | 2025-06-19 | Minotaur Therapeutics, Inc. | Humanized chimeric bovine antibodies and methods of use |
| CN113321740B (zh) * | 2021-05-08 | 2023-07-18 | 上海交通大学 | 一种融合蛋白及其制备方法和用途 |
| CN116655771A (zh) * | 2021-05-28 | 2023-08-29 | 苏州复融生物技术有限公司 | 一种新型白介素15突变体多肽的开发及其应用 |
| CA3220027A1 (en) * | 2021-05-28 | 2022-12-01 | Amato J. Giaccia | Bispecific fc fusion proteins with spd-1 and il-15 |
| KR20240043797A (ko) | 2021-08-13 | 2024-04-03 | 싸이튠 파마 | 암 치료용 IL-2/IL-15Rβγ 작용제와 항체-약물 접합체 조합 |
| CN116023503B (zh) * | 2021-10-25 | 2024-05-31 | 上海交通大学 | 一种融合蛋白及其制备方法和用途 |
| CA3238283A1 (en) * | 2021-11-15 | 2023-05-19 | Yangxin Fu | Fusion protein construct taking interleukin 15 as active ingredient and use thereof |
| CN115141283A (zh) * | 2022-03-10 | 2022-10-04 | 厦门柏慈生物科技有限公司 | 一种融合蛋白、制备方法及其应用 |
| CN119790066A (zh) * | 2022-08-05 | 2025-04-08 | 舒泰神(加州)生物科技有限公司 | 一种新型IL-15R alpha Fc融合蛋白及其使用 |
| US20260083832A1 (en) * | 2022-10-28 | 2026-03-26 | Nant Holdings Ip, Llc | Vaccine Composition For Stimulation Of Broad Spectrum Memory B Cell Expansion |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE299938T1 (de) | 1997-05-02 | 2005-08-15 | Genentech Inc | Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
| CN1703423A (zh) | 2002-10-14 | 2005-11-30 | 豪夫迈－罗氏公司 | Il－15拮抗剂 |
| ES2367027T3 (es) | 2004-02-27 | 2011-10-27 | Inserm (Institut National De La Santé Et De La Recherche Medicale) | Sitio de unión de la il-15 para il-15ralfa y mutantes específicos de il-15 que tienen actividad agonista/antagonista. |
| US20060257361A1 (en) | 2005-04-12 | 2006-11-16 | Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services | Novel form of interleukin-15, Fc-IL-15, and methods of use |
| EP1777294A1 (en) | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
| NZ599338A (en) | 2007-06-27 | 2013-11-29 | Marinepolymer Tech Inc | Complexes of il-15 and il-15ralpha and uses thereof |
| US8507222B2 (en) | 2010-09-21 | 2013-08-13 | Altor Bioscience Corporation | Multimeric IL-15 soluble fusion molecules and methods of making and using same |
| HUE042040T2 (hu) * | 2012-09-27 | 2019-06-28 | Merus Nv | Bispecifikus IGG antitestek mint T-sejt kapcsolók |
| US20150359853A1 (en) * | 2012-10-24 | 2015-12-17 | Admune Therapeutics Llc | Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes |
| RU2689717C2 (ru) * | 2014-01-08 | 2019-05-28 | Шанхай Хэнжуй Фармасьютикал Ко., Лтд. | Гетеродимерный белок il-15 и его применения |
| ES2811974T3 (es) | 2014-07-29 | 2021-03-15 | Novartis Ag | Regímenes de aumento escalonado de la dosis del heterodímero de il-15 e il-15ralfa para tratar afecciones |
| PL3235830T3 (pl) | 2014-12-19 | 2020-12-14 | Jiangsu Hengrui Medicine Co., Ltd. | Kompleks białkowy interleukiny 15 i jego zastosowanie |
| CN112574316A (zh) | 2015-07-02 | 2021-03-30 | 博际生物医药科技(杭州)有限公司 | 用于肿瘤靶向治疗的白细胞介素-15融合蛋白 |
| WO2017046200A1 (en) * | 2015-09-16 | 2017-03-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Specific interleukin-15 (il-15) antagonist polypeptide and uses thereof for the treatment of inflammatory and auto-immune diseases |
| MY203000A (en) | 2016-10-14 | 2024-06-01 | Xencor Inc | Il15/il15r� heterodimeric fc-fusion proteins |
| WO2019006472A1 (en) | 2017-06-30 | 2019-01-03 | Xencor, Inc. | TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS |
-
2019
- 2019-06-20 EP EP19822948.6A patent/EP3810171B1/en active Active
- 2019-06-20 WO PCT/US2019/038210 patent/WO2019246379A1/en not_active Ceased
- 2019-06-20 US US17/254,004 patent/US12319722B2/en active Active
- 2019-06-20 KR KR1020257027222A patent/KR20250130696A/ko active Pending
- 2019-06-20 CA CA3102821A patent/CA3102821A1/en active Pending
- 2019-06-20 JP JP2021520275A patent/JP7440102B2/ja active Active
- 2019-06-20 CN CN201980055119.XA patent/CN112584851B/zh active Active
- 2019-06-20 KR KR1020217002145A patent/KR102848197B1/ko active Active
- 2019-06-20 CN CN202511239681.1A patent/CN121086085A/zh active Pending
- 2019-06-20 AU AU2019288471A patent/AU2019288471B2/en active Active
-
2024
- 2024-02-07 JP JP2024016792A patent/JP7741574B2/ja active Active
-
2025
- 2025-02-19 AU AU2025201175A patent/AU2025201175A1/en active Pending
- 2025-05-03 US US19/197,991 patent/US20250388641A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250388641A1 (en) | 2025-12-25 |
| JP7741574B2 (ja) | 2025-09-18 |
| JP2024063004A (ja) | 2024-05-10 |
| JP2021528104A (ja) | 2021-10-21 |
| AU2025201175A1 (en) | 2025-03-13 |
| JP7440102B2 (ja) | 2024-02-28 |
| EP3810171A1 (en) | 2021-04-28 |
| AU2019288471B2 (en) | 2024-11-21 |
| KR102848197B1 (ko) | 2025-08-21 |
| US12319722B2 (en) | 2025-06-03 |
| EP3810171C0 (en) | 2025-07-09 |
| CN121086085A (zh) | 2025-12-09 |
| CA3102821A1 (en) | 2019-12-26 |
| AU2019288471A1 (en) | 2021-01-14 |
| CN112584851B (zh) | 2025-09-05 |
| US20220106374A1 (en) | 2022-04-07 |
| KR20210033994A (ko) | 2021-03-29 |
| EP3810171B1 (en) | 2025-07-09 |
| CN112584851A (zh) | 2021-03-30 |
| EP3810171A4 (en) | 2022-04-06 |
| WO2019246379A1 (en) | 2019-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102848197B1 (ko) | 신규한 인터루킨-15 (ｉｌ-15) 융합 단백질 및 이의 용도 | |
| JP7807076B2 (ja) | 新規インターロイキン－１５（ｉｌ－１５）融合タンパク質およびその使用 | |
| AU2020291942B2 (en) | Novel interleukin-2 variants for the treatment of cancer | |
| JP2022536347A (ja) | 新規インターロイキン－２バリアントおよびその二官能性融合分子 | |
| RU2833537C2 (ru) | Новые варианты интерлейкина-2 для лечения рака | |
| HK40074638B (zh) | 用於癌症治疗的新型白介素-2变体 | |
| HK40074638A (en) | Novel interleukin-2 variants for the treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A16 | Divisional, continuation or continuation in part application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PA0104 | Divisional application for international application |
St.27 status event code: A-0-1-A10-A16-div-PA0104 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| Q12 | Application published |
Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE) |